Abstract
Tumor treating fields (TTFields) are low-intensity electric fields alternating at an intermediate frequency (200kHz), which have been demonstrated to block cell division and interfere with organelle assembly. This novel treatment modality has shown promise in a variety of tumor types. It has been evaluated in randomized phase 3 trials in glioblastoma (GBM) and demonstrated to prolong progression-free survival (PFS) and overall survival (OS) when administered together with standard maintenance temozolomide (TMZ) chemotherapy in patients with newly diagnosed GBM. TTFields are continuously delivered by 4 transducer arrays consisting each of 9 insulated electrodes that are placed on the patient's shaved scalp and connected to a portable device. Here we summarize the preclinical data and mechanism of action, the available clinical data, and further outlook of this treatment modality in brain tumors and other cancer indications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1338-1349 |
| Number of pages | 12 |
| Journal | Neuro-oncology |
| Volume | 18 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2016 |
ASJC Scopus subject areas
- Clinical Neurology
- Oncology
- Cancer Research
